PLoS ONE (Jan 2021)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.

  • Fernando Franco,
  • Enric Carcereny,
  • Maria Guirado,
  • Ana L Ortega,
  • Rafael López-Castro,
  • Delvys Rodríguez-Abreu,
  • Rosario García-Campelo,
  • Edel Del Barco,
  • Oscar Juan,
  • Francisco Aparisi,
  • Jose L González-Larriba,
  • Manuel Domine,
  • Jose M Trigo,
  • Manuel Cobo,
  • Sara Cerezo,
  • Julia Calzas,
  • Bartomeu Massutí,
  • Joaquim Bosch-Barrera,
  • Paola García Coves,
  • Marta Domènech,
  • Mariano Provencio

DOI
https://doi.org/10.1371/journal.pone.0251761
Journal volume & issue
Vol. 16, no. 6
p. e0251761

Abstract

Read online

BackgroundSmall-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.Patients and methodsThis was an observational multicenter study that enrolled patients with lung cancer and thoracic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demographic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed.ResultsWith a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or ≥ 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty percent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overall survival was 9.5 months (95% CI 8.8-10.2 months), with an estimated rate of 70.3% (95% CI 67.2-73.4%), 38.9% (95% CI 35.4-42.4%), and 14.8% (95% CI 11.8-17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mortality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1-2. Long-term survival (> 2 years) was confirmed in 6.6% of patients, showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis.ConclusionThis study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients.